Bayer AG (OTCMKTS:BAYRY) has been assigned a consensus rating of “Buy” from the twelve brokerages that are currently covering the company. Three analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $111.00.

Several equities research analysts have issued reports on the company. Zacks Investment Research raised Bayer AG from a “hold” rating to a “buy” rating and set a $111.00 price target for the company in a research note on Monday, October 17th. Sanford C. Bernstein reissued a “buy” rating on shares of Bayer AG in a research note on Thursday, September 15th. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Bayer AG in a research note on Wednesday, September 14th. Finally, Citigroup Inc. raised Bayer AG from a “neutral” rating to a “buy” rating in a research note on Thursday, August 25th.

COPYRIGHT VIOLATION WARNING: “Bayer AG (BAYRY) Given Average Recommendation of “Buy” by Brokerages” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be read at

Shares of Bayer AG (OTCMKTS:BAYRY) traded down 0.85% during midday trading on Wednesday, hitting $93.67. The stock had a trading volume of 108,321 shares. The firm’s 50-day moving average price is $0.00 and its 200-day moving average price is $0.00. Bayer AG has a 1-year low of $92.84 and a 1-year high of $134.04.

Bayer AG (OTCMKTS:BAYRY) last posted its earnings results on Wednesday, October 26th. The company reported $1.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.13. Bayer AG had a return on equity of 24.12% and a net margin of 10.14%. On average, equities analysts expect that Bayer AG will post $8.07 earnings per share for the current year.

About Bayer AG

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures.

Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.